Enoticumab (REGN421, SAR153192) is an IgG1κ antibody that specifically targets human Delta-like ligand 4 (Dll4), which serves as a crucial component of the Notch signaling pathway and regulates the uptake of fatty acids through non-transcriptional modulation of macropinocytosis-dependent long-chain fatty acid absorption. Demonstrated efficacy in vivo, Enoticumab was shown to inhibit tumor growth by 86% and 83% in subcutaneous TOV-112D and intraperitoneal A2780 human ovarian tumor xenograft mouse models, respectively, when administered at a dose of 2.5 mg/kg weekly [1].